Literature DB >> 35714584

Beyond rare disorders: A new era for peroxisomal pathophysiology.

Einat Zalckvar1, Maya Schuldiner2.   

Abstract

Metabolism is emerging as a central influencer of multiple disease states in humans. Peroxisomes are central metabolic organelles whose decreased function gives rise to severe peroxisomal diseases. Recently, it is becoming clear that, beyond such rare inborn errors, the deterioration of peroxisomal functions contributes to multiple and prevalent diseases such as cancer, viral infection, diabetes, and neurodegeneration. Despite the clear importance of peroxisomes in common pathophysiological processes, research on the mechanisms underlying their contributions is still sparse. Here, we highlight the timeliness of focusing on peroxisomes in current research on central, abundant, and society-impacting human pathologies. As peroxisomes are now coming into the spotlight, it is clear that intensive research into these important organelles will enable a better understanding of their contribution to human health, serving as the basis to develop new diagnostic and therapeutic approaches to prevent and treat human diseases.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aging; cancer; diabetes; immunity; neurodegeneration; obesity; peroxisome; virus

Mesh:

Year:  2022        PMID: 35714584     DOI: 10.1016/j.molcel.2022.05.028

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   19.328


  2 in total

1.  Cellular metabolism therapy.

Authors:  Salvatore Nesci
Journal:  J Transl Med       Date:  2022-07-05       Impact factor: 8.440

2.  Systematic multi-level analysis of an organelle proteome reveals new peroxisomal functions.

Authors:  Eden Yifrach; Duncan Holbrook-Smith; Jérôme Bürgi; Alaa Othman; Miriam Eisenstein; Carlo Wt van Roermund; Wouter Visser; Asa Tirosh; Markus Rudowitz; Chen Bibi; Shahar Galor; Uri Weill; Amir Fadel; Yoav Peleg; Ralf Erdmann; Hans R Waterham; Ronald J A Wanders; Matthias Wilmanns; Nicola Zamboni; Maya Schuldiner; Einat Zalckvar
Journal:  Mol Syst Biol       Date:  2022-09       Impact factor: 13.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.